Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Trial Profile

Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Pharmacokinetics; Proof of concept
  • Acronyms PRISMA-1
  • Sponsors Rovi
  • Most Recent Events

    • 12 Jul 2016 Results published in the International Clinical Psychopharmacology
    • 26 Jun 2015 According to a ROVI media release, results of this study were presented at the 12th European Association for Clinical Pharmacology and Therapeutics (EACPT) Congress, 2015.
    • 26 Jun 2015 Results published in the ROVI Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top